$200M vaccine plant for China; Researchers advance bowel cancer vaccine;

Vaccine Market

Canada's Microbix Biosystems is plotting a $200 million flu vaccine plant in Hunan province. The cooperative deal puts Microbix in partnership with the Hunan government, which will put up $100 million of the funding. The rest will come from Microbix's licensing partners. Report

Supply constraints for an ingredient in a shingles vaccine has forced Merck to warn about looming shipping delays for Zostavax. Article

Health officials in the U.S. are hoping that a new 5-in-1 vaccine will improve compliance on recommended vaccinations in the U.S. by reducing the complex number of vaccinations that are recommended. Story

Canada's Bioniche Life Sciences says it has secured the financing necessary to scale-up its vaccine production facility. Story

Vaccine Research

Insight into the unique immune system of intestines has helped advance an experimental bowel cancer vaccine, say researchers at the Kimmel Cancer Centre at Thomas Jefferson University. Article

DynPort Vaccine has won the federal contract to develop a new plague vaccine. Story

Medicago announced additional positive results for its H5N1 avian flu vaccine from a preclinical immunogenicity study performed in ferrets. Release

The Albany Medical College has won a $5.4 million grant to work on a new universal flu vaccine. Report

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.